Opioid receptors are currently classed as 
the guanine nucleotide-bindin protein (G-proteln)-coupled form and the uncoupled form of each receptor. As evidence for this proposal, the [3Hlbremazocine binding suffered little or no loss with G-protein-uncoupling treatments, whereas binding of other opioid agonists was fully sensitive. We conclude that [3Hlbremazocine offers a tool for the measurement of the total pools of coupled and uncoupled opiold receptors and that much of the previous characterization of opiold receptor subtypes reflects, instead, a si t pool of G-protein-uncoupled oploid receptors.
The receptors for endogenous opioids are currently divided into three generally accepted types, namely, ,u, 8, and K. It is widely accepted that these receptors are members of the guanine nucleotide-binding protein (G protein)-linked superfamily and their responses show characteristics of being mediated by a second messenger system. Precise pharmacological characterization of the opioid receptor types was delayed until the synthesis and use of type-selective ligands such as [D-Ala2,MePhe4,Glycol5ienkephalin (DAGO) [for A (1) ] and [D-Penz,D-Pen5]enkephalin [for 8 (2) ]. Characterization ofthe K type receptors was particularly difficult because, in radioligand binding studies, the K type initially had to be measured as the residual binding of nonselective opiods after the ju and 8 types were suppressed by ;-and 8-selective agonists (1) . The nonselective radioligands most commonly used for this purpose were the benzomorphans bremazocine and ethylketocyclazocine (EKC). Pharmacological studies have indicated that bremazocine is an antagonist/partial agonist at K sites, a partial agonist or antagonist at 8 sites, and an antagonist at jL sites (3) (4) (5) (6) (7) (8) . More recently, K binding sites have been measured by a 3H-labeled arylacetamide series of ligands that include the agonists 5a,7a,88-(-)-N-methyl,N-[(7-(1-pyrrolidinyl)-1-oxaspiro(4,5)-dec-8-yl)]benzeneacetamide (U69593) (9) and (+)-trans-N-methyl,N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide hydrochloride (PD117302) (10) . However, it has been found that these compounds recognize only a fraction of the binding sites defined, by the suppression method, as K (9, 10) . This and similar evidence has led to proposals for K receptor subtypes (11) (12) (13) (14) (15) (16, 17) . pINHlppG promotes the dissociation of receptor-G-protein-agonist complexes (18) . Similarly, exposure of membrane preparations to a high pH can inactivate G proteins, leaving P-, a,-, and aradrenergic receptors intact but lacking high-affinity agonist binding (19, 20) Fig. 2A and Table 1 ). The bremazocine binding could be fully inhibited with high affinity by the 8-preferring DADLE and DPDPE (Fig. 2B ) and also by naloxone (Table 2) , whereas ligands selective for K (U50488 and PD117302) and A (DAGO) sites bound with far lower affinity ( Fig. 2B and Table 2 (Figs. 1-3 states of the receptor may explain the low efficacy of this compound (4, 5) . Agonist efficacy has been correlated with the ratio of affinities at analogous states of the muscarinic and j-adrenergic receptors (28, 29) . Our interpretation of opioid receptor ligand binding could explain many of the deductions of apparent K receptor multiplicity that have been made (for example, see refs. 11-15). These are mostly based upon observations that the binding of nonselective opioid radioligands, in the presence of agents that block binding at jL and 8 sites, can be divided into sites that are sensitive and insensitive to various K agonists. When autoradiography was used, local variations in residual endogenous ligands and reagent impermeability could account for aberrant heterogeneity. In some membrane studies (13, 14) , the relative abundances and properties of two classes of sites that have been seen by others are consistent with our data. In other cases, very different conditions of temperature, medium composition, and higher radioligand concentration than we used were applied: some uncoupled K receptors may also be labeled then where we (using, e.g., [3H]EKC) label only the coupled state. In any case, our observations show that this method is likely to show apparent K receptor multiplicity even when only ,u, 8 , and K opioid types are present. (i) The ligands used to block binding at,u and 8 sites are generally agonists, so that they will bind with higher affinity to the coupled than to the uncoupled states of,u and 8 sites. This may leave radioligand binding at the uncoupled ,t and 8 sites largely unsuppressed. (ii) Since the compounds used to label the K site(s) (e.g., U69593) are also agonists, they, too, will show strongly differential affinity for the coupled and the uncoupled states; apparent heterogeneity may be observed even if all binding at A and 8 sites was suppressed. (iii) It has been pointed out (30) that several states of a single receptor type may exist, due to G-protein equilibria, that have different agonist affinities, further complicating interpretation of such data. Hence, it is not at all surprising that an apparent heterogeneity of K receptors is observed, but this need not have a relation to the true subtypes present. An analogous situation occurred with dopamine receptors (31) , when the putative receptor subtypes identified were shown to be G-protein-coupled and -uncoupled states of the same receptors. Those putative subtypes did not correspond to the actual subtypes now known from DNA cloning; the same situation may well apply to the actual subtypes of the K receptor when cloned.
In conclusion, we find that the K receptor in its coupled state can at present best be recognized by the high-affinity binding of specific [3H] 
